This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research(VOYAGER)Study

This study has been completed.
Information provided by (Responsible Party):
Koshiro Fukiyama, Kitakyushu-Tsuyazaki Hospital Identifier:
First received: March 28, 2007
Last updated: December 5, 2013
Last verified: December 2013
The purpose of this study is to compare improvement percentage of urinary albumin excretion between valsartan 80 mg- and valsartan 160 mg-based therapy in patient with morning hypertension.

Condition Intervention Phase
Hypertension Drug: Valsartan 80mg daily Drug: Valsartan 160mg daily Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Study on Optimal Anti-hypertensive Therapy With Valsartan by Using Home Blood Pressure Measurement

Resource links provided by NLM:

Further study details as provided by Koshiro Fukiyama, Kitakyushu-Tsuyazaki Hospital:

Primary Outcome Measures:
  • Improvement percentage of urinary albumin excretion [ Time Frame: 3, 6, 9, and 12 months ]

Secondary Outcome Measures:
  • home blood pressure; hospital blood pressure; stroke; cardiovascular disease; microangiopathy [ Time Frame: every month ]

Enrollment: 103
Study Start Date: July 2006
Study Completion Date: November 2013
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Valsartan Drug: Valsartan 80mg daily Drug: Valsartan 160mg daily

Detailed Description:

The cardiovascular diseases such as stroke and myocardial infarction consist 50% of the cause of death in Japanese population. Numerous mega trials have shown that strict anti-hypertensive therapy could reduce cardiovascular morbidity and mortality in hypertensive patients.

It is reported, however, over 50% hypertensive patients have not been controlled below therapeutic target blood pressure that the JSH2004 guideline recommends.

Recently use of Angiotensin II receptor blockers (ARBs) is increasing progressively for their pharmacological action on organ protection as well as potent reduction in blood pressure. However, usual dosage of ARB in Japan is almost half of that in the mega trials executed in Europe and America. Lower dosage compared to western countries might be a reason why cardiovascular events are not fully reduced in Japan.

Valsartan optimal therapy against elevated home blood pressure research (VOYAGER) study will be a multi-center, open-label, randomized, active-controlled study to evaluate the following; improvement percentage of urinary albumin exception, home blood pressure, hospital blood pressure, incidence of stroke, cardiovascular disease, and microangiopathy with valsartan 80 mg- or valsartan 160 mg based therapy in patients with elevated morning home blood pressure.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Outpatients aged over 20 years and less than 80 years, regardless of sex.
  • Patients with stable seated morning home blood pressure of over 135 mmHg and/or diastolic blood pressure of over 85 mmHg within 1 to 2 weeks.
  • Patients who are on therapy with conventional dosage of ARB.

Exclusion Criteria:

  • Patients who are difficult to measure home blood pressure.
  • Patients with secondary hypertension or malignant hypertension.
  • Patients with seated systolic blood pressure of over 200 mmHg.
  • Patients with seated diastolic blood pressure of over 120 mmHg.
  • Patients with a history of cerebrovascular disorder or myocardial infarction or heart failure within 6 months prior to enrolment in the study.
  • Patients with atrial fibrillation, atrial flutter, or serious arrhythmia.
  • Patients with renal dysfunction with serum creatinine level of over 2 mg/dL.
  • Patients with serious liver dysfunction.
  • Patient with HbA1C of over 8 percent.
  • Patient with positive albuminuria by dip and read stick test.
  • Patient treated with any angiotensin converting enzyme inhibitor
  • Pregnant women
  • Patients with a history of hypersensitivity to valsartan.
  • Other patients who are judged to be inappropriate for the study by the investigator or sub-investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00460213

Koshiro Fukiyama
Kitakyushu, Fukuoka, Japan, 808-0024
Sponsors and Collaborators
Kitakyushu-Tsuyazaki Hospital
Study Chair: Koshiro Fukiyama, MD Japan Seamen's Relief Association Moji Hospital
  More Information

Responsible Party: Koshiro Fukiyama, Honorary Director, Kitakyushu-Tsuyazaki Hospital Identifier: NCT00460213     History of Changes
Other Study ID Numbers: KIT-061003-1
Study First Received: March 28, 2007
Last Updated: December 5, 2013

Keywords provided by Koshiro Fukiyama, Kitakyushu-Tsuyazaki Hospital:
home blood pressure

Additional relevant MeSH terms:
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017